Heron Therapeutics Announces Executive & Director Compensation Changes

TL;DR

Heron Therapeutics (HRTX) filed an 8-K detailing exec/director comp changes and new board members.

AI Summary

Heron Therapeutics, Inc. announced on October 27, 2025, changes in its executive and director compensation arrangements. The filing details the election of new directors and the appointment of certain officers, alongside updates to compensatory arrangements for key personnel. This report also includes financial statements and exhibits relevant to these corporate governance and compensation matters.

Why It Matters

Changes in executive and director compensation can signal shifts in company strategy, performance expectations, or governance, potentially impacting investor confidence and future financial performance.

Risk Assessment

Risk Level: medium — Changes in executive and director compensation, board composition, and the filing of financial statements can indicate significant internal shifts that may affect the company's future performance and stock price.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• October 27, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-33221 (company_id) — Commission File Number
• 94-2875566 (company_id) — I.R.S. Employer Identification No.
• 100 Regency Forest Drive, Suite 300, Cary, NC 27518 (address) — Address of principal executive offices
• AP PHARMA INC /DE/ (company) — Former company name
• ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former company name

FAQ

From the Filing

0001193125-25-256300.txt : 20251029 0001193125-25-256300.hdr.sgml : 20251029 20251029160533 ACCESSION NUMBER: 0001193125-25-256300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20251027 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251029 DATE AS OF CHANGE: 20251029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 251429955 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-20251027.htm 8-K 8-K false 0000818033 0000818033 2025-10-27 2025-10-27   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (858) 251-4400 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share HRTX The Nasdaq  Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 27, 2025, the Board of Directors (the “Board”) of Heron Therapeutics, Inc. (the “Company”) appointed Thomas Cusack to the Board to serve for a term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified or until his earlier death